QX008N
Asthma, COPD
Phase 1Active
Key Facts
About Qyuns Therapeutics
Publicly traded biotech developing antibody therapies for autoimmune and allergic diseases with a pipeline targeting IL-4Rα, IL-17A, IL-23, and TSLP pathways.
View full company profileTherapeutic Areas
Other Asthma, COPD Drugs
| Drug | Company | Phase |
|---|---|---|
| HBM9378 (SKB378/WIN378) | Harbour BioMed | Phase 1 |
| HP-Betadex DPI Formulations | Aquilon Pharmaceuticals | Clinical |
| Generic Advair (Fluticasone/Salmeterol) | Lupin Limited | ANDA Filed/Approved |
| Respiratory Inhalation Portfolio (Generic) | Cipla | ANDA Filed/Approved |
| Wixela Inhub (Fluticasone/Salmeterol) | Viatris | Launched |
| RELVAR/BREO ELLIPTA | Innoviva | Commercial |